Lv3
388 积分 2022-05-23 加入
DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors
6天前
已关闭
AB1034 CHARACTERIZATION OF RO7507062, A CD19-TARGETING T-CELL BISPECIFIC ANTIBODY (CD19TCB), AND DESIGN OF A PHASE 1 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS
19天前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
1个月前
已完结
Non-depleting anti-CD19 B cell inhibition
2个月前
已完结
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells
2个月前
已完结
How to improve R&D productivity: the pharmaceutical industry's grand challenge
3个月前
已完结
How to improve R&D productivity: the pharmaceutical industry's grand challenge
3个月前
已完结
Advances in bispecific biotherapeutics for the treatment of cancer
3个月前
已完结
Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions
3个月前
已完结
抗肿瘤药物申报联合用药早期临床试验的考虑
3个月前
已完结
皖公网安备34019202002308
